BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces the activation of Ottawa Heart Institute, the first Canadian clinical investigational site for the CardiAMP® Cell Therapy Heart Failure Trial.
“The Ottawa Heart Institute is the first of four planned world-class Canadian clinical sites able to enroll patients in the CardiAMP Cell Therapy Heart Failure Trial,” said Dr. Peter Altman, BioCardia CEO. “Our expectation is that each site will contribute six patients per year to the ongoing pivotal trial enrollment in the U.S. and facilitate completion of this important pivotal trial. We are honored to be working with the team at Ottawa Heart.”
The Canadian National Principal Investigator is Duncan Stewart, M.D., a globally recognized physician leader in developing cell and gene-based therapies for cardiovascular and lung disease, who leads the prestigious Ottawa Heart Institute. The lead study site Investigators at Ottawa Heart Institute are Principal Investigator Darryl Davis, M.D., a clinician-scientist and cardiac electrophysiologist who directs the cardiac translational research laboratory, and Lisa Marie Mielniczuk, M.D., Director of the Heart Failure Program at University of Ottawa.
The CardiAMP Cell Therapy Heart Failure trial is scheduled to have a prespecified formal Data Safety Monitoring Board Review on August 30, 2022, which will assess both safety and futility of the trial. Results from this review should be available in the days following the review.
Patients interested in learning about the CardiAMP Cell Therapy Heart Failure Trial may visit www.cardiamp.com or clinicaltrials.gov, referencing trial NCT02438306 for more information.
